REGENERON PHARMACEUTICALS, INC. Form SCHEDULE 13G: Beneficial ownership report (passive)
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-04-30: Form SCHEDULE 13G; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X02/primary_doc.xml.
- 2026-03-27: Form SCHEDULE 13G/A; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X02/primary_doc.xml.
- 2025-08-06: Form SCHEDULE 13G/A; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X01/primary_doc.xml.
- 2025-06-05: Form SCHEDULE 13G/A; Description Beneficial ownership report (passive); Document xslSCHEDULE_13G_X01/primary_doc.xml.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-04-30 | SCHEDULE 13G | Beneficial ownership report (passive) | xslSCHEDULE_13G_X02/primary_doc.xml | |
| 2026-03-27 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X02/primary_doc.xml | |
| 2025-08-06 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X01/primary_doc.xml | |
| 2025-06-05 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X01/primary_doc.xml | |
| 2025-04-22 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X01/primary_doc.xml | |
| 2025-02-12 | SCHEDULE 13G/A | Beneficial ownership report (passive) | xslSCHEDULE_13G_X01/primary_doc.xml |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |